Rabbit Models for Alzheimer's Disease

submitted by: alex01

Diana Woodruff-Pak (Temple University, Philadelphia, PA) used cholesterol-fed rabbits as a model of AD for evaluation of currently available and potential anti-Alzheimer drugs. These animals developed typical Alzheimer pathology, including behavioral changes and deposition of ß-amyloid and even
tau. Galantamine and donepezil partially protected animals from Alzheimer symptomatology.

Cytokines and Neutrophins in Neuroprotection

submitted by: alex01
Dr. Michael Spedding published recently a review on the role of cytokines and neurotrophins in disease. Neurotrophins (e.g. BDNF) have beneficial effects on neuronal plasticity and brain metabolism. Inflammatory cytokines (e.g. IL1beta)oppose the effects of neurotrophins. Both, neurotrophins and cytokines are targets for the development of new drugs affecting central nervous system. Brain-derived neurotrophic factor (BDNF) is the main activity-dependent neurotrophic factor. Interleukin 1beta...

AMPA Ligands in Neuroprotection

submitted by: alex01
Michael Spedding (Institute Internatinales Servier, Paris, France) described how neuroprotection can be achieved by either by blockade or by stimulation of AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors. Low threshold AMPA receptor stimulation leads to the release of BDNF (brain-derived neurotrophic factor) which is neuroprotective. Blockade of AMPA receptors reduces excitotoxicity leading to neuroprotection. BDNF is a major activity-dependent neurotrophic factor...

Alzheimer's Disease

submitted by: alex01
Z. Khachaturian, PhD. - New approaches to the therapy of Alzheimer’s disease (AD) are discussed in video interviews of this series. According to Z. Khachaturian (Potomac, MD) substantial progress has been made during the last 10 years in our understanding of pathogenesis of Alzheimer’s disease as well as in the discovery of biomarkers and therapeutic approaches. In addition to cholinergic drugs, inhibitors of plaque formation have been discovered, but the currently available...

Drug Discovery for Alzheimer's Disease

submitted by: alex01

Gregory Rose from PharmExperts.com interviews J. Buccafusco (Medical College of Georgia, Augusta, GA) about his development of new anti-Altzheimer drugs, designed to act by multiple mechanisms to improve congnition. Desensitization of nicotinic receptors is one of the novel approaches proposed by Buccafusco. Three of his compounds are currently in advanced preclinical evaluation.